Clarivate’s Epidemiology’s coverage of the RSV vaccine comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of the RSV vaccine for each country, as well as annualized case counts projected to the national population.
Clarivate’s Epidemiology’s RSV vaccine forecast will answer the following questions:
All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate’s Epidemiology provides at least ten years of forecast data for the following RSV vaccine patient populations:
Vaccine eligible population
Newly eligible for vaccine population
Note: coverage may vary by country and region.